Antibiotics Market Analysis- Global Supply & Demand Analysis & Opportunity Outlook 2023-2035

Global Antibiotics Market Highlights Over 2023 - 2035

The global antibiotics market is estimated to garner a notable revenue by the end of 2035 by growing at a CAGR of ~8% over the forecast period, i.e., 2023 – 2035. Further, the market generated a revenue of USD 43 Billion in the year 2022. The growth of the market is primarily attributed to the worldwide growing prevalence of various communicable diseases, such as TB, HIV, and others. As per the World Health Organization (WHO) statistics, in 2020, an estimated 1.5 million (UI 1.0 to 2.0 million) people were infected with HIV for the first time. This brought the global HIV population to 38.4 million people by 2021.

Antibiotics-market-overview Get more information on this report:Request Sample PDF

Antibiotics are antibacterial compounds that are active against bacteria. It is the most common type of antibacterial agent used to treat bacterial infections. Antibiotic medications are commonly used to treat and prevent such infections. They either kill or inhibit bacterial growth. Such factor is leading up the growing consumption of various types of antibiotics across the globe. For instance, global antibiotic consumption rates surged by 47% between 2000 and 2018 (from 9.8 to 14.3 defined daily doses (DDD) per 1000 people per day).

Get more information on this report: Request Free Sample PDF

Global Antibiotics Market: Key Insights

Base Year	2022
Forecast Year	2023-2035
CAGR	~8%
Market Size in Base Year (2022)	~ USD 43 Billion
Market Size in Forecast Year (2035)	~ USD 108 Billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)

Global Antibiotics Market: Growth Drivers and Challenges

Growth Drivers

Growing Prevalence of Respiratory Diseases - The respiratory system is a group of organs that regulates breathing. The lungs are the system's main organ, and it also consists of the pharynx, larynx, trachea, nasal tube, oral cavity, pharynx, and bronchi and bronchioles. Respiratory diseases are one of the leading causes of death worldwide. These diseases need a preferred dose of antibiotics to control the further spread of bacteria. Therefore, growing prevalence of respiratory diseases is fueling up the antibiotics market growth. As per the World Health Organization statistics, globally, nearly 262 million individuals have been suffering from asthma.
Surge in Drug Combinations Over Mono-Therapy – It was observed in a clinical study that a database for antifungal therapy has nearly 5,517 medicines in 8,129 combinations that have been evaluated against 240 strains, yielding 491,126 samples.
Escalation in Urinary Tract Infections (UTIs) – For instance, every year, more than 8 million patients with urinary tract infections (UTIs) seek medical treatment. About 61% of women and 13% of men are predicted to get at least one UTI in their lives.
Boost in Global Burden of Bacterial Skin Diseases – Globally, the age-standardized estimated incidence of bacterial skin diseases was reached around 161 million for males and 133 million for females in 2019.
Growing Number of Older-Aged Population - According to the statistics of World Health Organization, the global population of people aged 60 and up is projected to increase from 1 billion in 2020 to 1.4 billion by 2030.

Challenges

Side Effects Associated with Antibiotics - Antibiotic side effects can include allergic reactions and severe, sometimes fatal diarrhea brought on by the bacterium Clostridium difficile (C. diff). Additionally, antibiotics may conflict with other medications.
Stringent Regulatory Procedures
Escalation in Antibiotic Resistance

The global antibiotics market is segmented and analyzed for demand and supply by indication into skin infections, respiratory, gastrointestinal, UTIs, blood stream, clostridium difficile, ear infections, and others. Out of these, the gastrointestinal segment is projected to significantly grow over the forecast period on the back of increasing prevalence of acute infectious diarrhea in children across the globe. For instance, acute infectious diarrhea is one of the most serious conditions in the world and is accountable for 1 million to 2.5 million deaths per year. Globally, more than 2 to 5 billion kids are affected every year.

Market Segmentation

Our in-depth analysis of the global antibiotics market includes the following segments:

By Drug Class	Beta Lactam & Beta Lactamase Inhibitors Macrolide Others
By Drug Origin	Natural Semisynthetic Synthetic
By Spectrum of Activity	Broad-Spectrum Narrow-Spectrum Antibiotics
By Indication	Skin Infections Respiratory Gastrointestinal UTIs Blood Stream Clostridium Difficile Ear Infections Others
By End-User	Hospitals Specialty Clinics Others

Get more information on this report: Request Free Sample PDF

Top Featured Companies Dominating the Global Antibiotics Market

F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

GlaxoSmithKline plc
Bristol-Myers Squibb Company
Teva Pharmaceuticals Industries Ltd.
Pfizer Inc.
Abbott Laboratories
Merck & Co., Inc.
Lupin Limited
Melinta Therapeutics, LLC
Bayer AG

In The News

GlaxoSmithKline plc and Spero Therapeutics have announced an exclusive license agreement for tebipenem pivoxil hydrobromide (tebipenem HBr), a late-stage antibiotic that is anticipated to be used to treat complex urinary tract infections. Its 3^rd phase clinical trial is estimated to start in 2023.
Teva Pharmaceuticals Industries Ltd. announced the launch of its 250 mg and 500 mg strength generic Erythromycin tablets as a therapeutic equivalent to Arbor Pharmaceuticals' reference listed drug (RLD) Erythromycin Tablets. A variety of bacterial infections and rheumatic fever attacks are projected to be treated with these tablets in patients allergic to penicillin.

Global Economic Impact

Request Insights

Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the antibiotics market?

Ans: Growing prevalence of respiratory diseases, surge in drug combinations over mono-therapy, escalation in urinary tract infections (UTIs) are some major factors driving the growth of the market.

2) What would be the CAGR of antibiotics market over the forecast period?

Ans: The market is anticipated to attain a CAGR of ~8% over the forecast period, i.e., 2023 – 2035.

3) What are the challenges affecting the antibiotics market growth?

Ans: Side effects associated with antibiotics, stringent regulatory procedures, and escalation in antibiotic resistance are estimated to hamper the market growth.

4) Which region will provide more business opportunities for growth of antibiotics market in future?

Ans: The market in Asia Pacific is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

5) Who are the major players dominating the antibiotics market?

Ans: The major players in the market are F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Pfizer Inc., Abbott Laboratories, Merck & Co., Inc., and others.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the antibiotics market?

Ans: The market is segmented by drug class, drug origin, spectrum of activity, indication, end-user, and by region.

8) Which segment captures the largest market size in indication segment in the antibiotics market?

Ans: The gastrointestinal segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.